Replimune Group Stock Investor Sentiment
| REPL Stock | USD 13.26 1.67 11.19% |
About 54% of Replimune's investor base is interested to short. The analysis of the overall investor sentiment regarding Replimune Group suggests that many traders are impartial. Replimune's investing sentiment shows overall attitude of investors towards Replimune Group.
Replimune |
Replimune Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Replimune can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Replimune that are available to investors today. That information is available publicly through Replimune media outlets and privately through word of mouth or via Replimune internal channels. However, regardless of the origin, that massive amount of Replimune data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Replimune news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Replimune relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Replimune's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Replimune alpha.
Replimune Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 50000 shares by Astley-sparke Philip of Replimune subject to Rule 16b-3 | 08/30/2024 |
2 | Insider Trading | 09/04/2024 |
3 | Disposition of 5255 shares by Christopher Sarchi of Replimune at 10.92 subject to Rule 16b-3 | 09/20/2024 |
4 | Insiders At Replimune Group Sold US863k In Stock, Alluding To Potential Weakness | 10/02/2024 |
5 | Acquisition by Christopher Sarchi of 66675 shares of Replimune at 7.73 subject to Rule 16b-3 | 10/04/2024 |
6 | Morgan Stanleys Strategic Reduction in Replimune Group Inc Holdings - Yahoo Finance | 10/07/2024 |
7 | Replimune Announces Inducement Grants Under NasdaqListing Rule 5635 | 10/09/2024 |
8 | Acquisition by Jean Franchi of 67500 shares of Replimune at 17.66 subject to Rule 16b-3 | 11/01/2024 |
9 | Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 11/08/2024 |
10 | Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update | 11/12/2024 |
11 | Disposition of 5207 shares by Christopher Sarchi of Replimune at 10.78 subject to Rule 16b-3 | 11/18/2024 |
12 | Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License ... | 11/21/2024 |
13 | SP 500 Moves Higher Intuit Shares Fall Following Q1 Results | 11/22/2024 |
Check out Replimune Hype Analysis, Replimune Correlation and Replimune Performance. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.04) | Return On Assets (0.27) | Return On Equity (0.50) |
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.